Standardized ethanol extract of Tinospora crispa upregulates pro-inflammatory mediators release in LPS-primed U937 human macrophages through stimulation of MAPK, NF-κB and PI3K-Akt signaling networks.
Down-Regulation
Humans
Inflammation Mediators
/ metabolism
Lipopolysaccharides
Malaysia
Mitogen-Activated Protein Kinases
/ metabolism
NF-kappa B
/ metabolism
Phosphatidylinositol 3-Kinases
/ metabolism
Plant Extracts
/ pharmacology
Plant Stems
Proto-Oncogene Proteins c-akt
/ metabolism
Signal Transduction
Tinospora
U937 Cells
Up-Regulation
Immunostimulatory actions
MAPKs
NF-κB
PI3K-Akt
Pro-inflammatory cytokines
Tinospora crispa
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
06 Aug 2020
06 Aug 2020
Historique:
received:
06
03
2020
accepted:
27
07
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
2
2
2021
Statut:
epublish
Résumé
Immunomodulatory effects of Tinospora crispa have been investigated due to its traditional use to treat several inflammatory disorders associated to the immune system. The present study reports the underlying mechanisms involved in the stimulation of 80% ethanol extract of T. crispa stems on pro-inflammatory mediators release in lipopolysaccharide (LPS)-primed U937 human macrophages via MyD88-dependent pathways. Release of interleukin (IL)-1β and tumor necrosis factor (TNF)-α, and production of prostaglandin E Qualitative and quantitative analyses of chromatographic data indicated that syringin and magnoflorine were found as the major components of the extract. T. crispa-treatment prompted activation of NF-κB by enhancing IKKα/β and NF-κB (p65) phosphorylation, and degradation of IκBα. The extract upregulated COX-2 protein expression, release of pro-inflammatory mediators and MAPKs (ERK, p38 and JNK) phosphorylation as well as Akt dose-dependently. T. crispa extract also upregulated the upstream signaling adaptor molecules, toll-like receptor 4 (TLR4) and MyD88. T. crispa-treatment also upregulated the pro-inflammatory markers mRNA expression. The results suggested that T. crispa extract stimulated the MyD88-dependent signaling pathways by upregulating the various immune inflammatory related parameters.
Sections du résumé
BACKGROUND
BACKGROUND
Immunomodulatory effects of Tinospora crispa have been investigated due to its traditional use to treat several inflammatory disorders associated to the immune system. The present study reports the underlying mechanisms involved in the stimulation of 80% ethanol extract of T. crispa stems on pro-inflammatory mediators release in lipopolysaccharide (LPS)-primed U937 human macrophages via MyD88-dependent pathways.
METHODS
METHODS
Release of interleukin (IL)-1β and tumor necrosis factor (TNF)-α, and production of prostaglandin E
RESULTS
RESULTS
Qualitative and quantitative analyses of chromatographic data indicated that syringin and magnoflorine were found as the major components of the extract. T. crispa-treatment prompted activation of NF-κB by enhancing IKKα/β and NF-κB (p65) phosphorylation, and degradation of IκBα. The extract upregulated COX-2 protein expression, release of pro-inflammatory mediators and MAPKs (ERK, p38 and JNK) phosphorylation as well as Akt dose-dependently. T. crispa extract also upregulated the upstream signaling adaptor molecules, toll-like receptor 4 (TLR4) and MyD88. T. crispa-treatment also upregulated the pro-inflammatory markers mRNA expression.
CONCLUSION
CONCLUSIONS
The results suggested that T. crispa extract stimulated the MyD88-dependent signaling pathways by upregulating the various immune inflammatory related parameters.
Identifiants
pubmed: 32762741
doi: 10.1186/s12906-020-03039-7
pii: 10.1186/s12906-020-03039-7
pmc: PMC7409646
doi:
Substances chimiques
Inflammation Mediators
0
Lipopolysaccharides
0
NF-kappa B
0
Plant Extracts
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Subventions
Organisme : Kementerian Pertanian dan Industri Asas Tani Malaysia
ID : NH1015D075
Références
Lancet. 1976 Feb 21;1(7956):393-5
pubmed: 55652
Int Immunopharmacol. 2018 Jul;60:141-151
pubmed: 29730557
J Ethnopharmacol. 2017 Jul 31;207:67-85
pubmed: 28629816
J Biol Chem. 1996 May 17;271(20):11911-9
pubmed: 8662618
Drug Des Devel Ther. 2015 Jun 10;9:2961-73
pubmed: 26089645
Mediators Inflamm. 2014;2014:561459
pubmed: 24876674
Exp Mol Med. 2013 Feb 22;45:e11
pubmed: 23429360
Food Funct. 2017 Oct 18;8(10):3410-3431
pubmed: 28714500
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
J Appl Toxicol. 2009 Mar;29(2):91-100
pubmed: 18937212
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
Osteoarthritis Cartilage. 2006 Sep;14(9):839-48
pubmed: 16730463
Biochem J. 1994 Sep 15;302 ( Pt 3):723-7
pubmed: 7945196
Phytother Res. 2018 Dec;32(12):2510-2519
pubmed: 30238535
Front Pharmacol. 2017 Jan 30;8:22
pubmed: 28194110
Br J Pharmacol. 2013 Nov;170(5):1078-91
pubmed: 23941302
Inflammation. 2018 Jun;41(3):984-995
pubmed: 29427163
Glia. 2011 Feb;59(2):242-55
pubmed: 21125645
BMC Complement Altern Med. 2014 Jun 27;14:205
pubmed: 24969238
Adv Immunol. 1995;58:1-27
pubmed: 7741027
Int Immunopharmacol. 2017 Sep;50:291-304
pubmed: 28734166
J Leukoc Biol. 1999 Jan;65(1):50-8
pubmed: 9886246
Int Immunopharmacol. 2018 Feb;55:312-322
pubmed: 29310107
Food Funct. 2016 Mar;7(3):1380-9
pubmed: 26839149
BMC Complement Altern Med. 2018 Jul 25;18(1):224
pubmed: 30045725
Cytokine Growth Factor Rev. 1996 Aug;7(2):175-90
pubmed: 8899295
Front Plant Sci. 2015 Aug 25;6:655
pubmed: 26379683
Planta Med. 2018 Nov;84(17):1255-1264
pubmed: 29906814
Int Immunopharmacol. 2013 Nov;17(3):698-703
pubmed: 24012524
J Biol Chem. 1997 Aug 22;272(34):21096-103
pubmed: 9261113
Nat Rev Immunol. 2009 Nov;9(11):778-88
pubmed: 19855404
Front Pharmacol. 2016 Mar 21;7:59
pubmed: 27047378
J Immunol. 2012 Mar 15;188(6):2847-57
pubmed: 22312125